-
CanSino BiologicsLaunches Phase III Trial for DTcP Vaccine in Infants and Young Children
•
CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of a Phase III clinical study for its DTcP vaccine, targeting infants and young children under 2 years old. This development is accompanied by the enrollment of the first subjects in the trial. Quality Consistency and…
-
Hunan HSA Implements Direct BMI Fund Payments for VBP-Winning Drugs and Consumables
•
The Hunan Healthcare Security Administration (HSA) bureau has released a notice stating that effective from October 1, 2023, payments for drugs or medical consumables that win volume-based procurement (VBP) tenders will be settled directly by the Basic Medical Insurance (BMI) funds. This change implies that hospitals will no longer handle…
-
SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China
•
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries, has released a notification aimed at increasing the regulation of forums, summits, annual meetings, and other conference activities with a forum nature across the country. The document outlines 10 requirements to standardize these events. Compliance…
-
Cutia Therapeutics’ CU-10201 Enters Priority Review for Acne Treatment in China
•
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its CU-10201, a 4% minocycline foam agent for external use, has entered into priority review for the treatment of non-nodular moderate to severe acne vulgaris in individuals aged 9 and above in China. CU-10201: A Novel Pediatric Dosage Form for…
-
Huadong Medicine Secures Exclusive Rights to Arcutis’ Daxas in Greater China and South-East Asia
•
Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant licensing agreement with Arcutis (NASDAQ: ARQT), securing exclusive rights to develop, file for regulatory approval, manufacture, and commercialize Arcutis’ Daxas (roflumilast, including cream ZORYVE and foam agent ARQ-154) external preparations in Greater China and South-East Asia. Financial Terms and CommitmentsUnder…
-
Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China
•
US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group Asia Pacific Medical Group (APMG) with the aim of enhancing the implementation and promotion of advanced orthopedic and extrasomatic diagnosis and treatment services in China. Launch of AiBLE Digital Intelligence Orthopedics Integrated SolutionIn a significant…
-
Everest Medicines and Shanghai Pharmaceuticals Deepen Partnership for Drug Distribution in China
•
China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a significant multi-dimension tie-up that builds upon their existing collaboration in product distribution, access, and retail. This alliance, which began in April 2023, initially focused on the import and distribution of Xerava (eravacycline) in mainland China.…
-
NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma
•
The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co., Ltd’s GPRC5D-targeted chimeric antigen receptor (CAR)-T cell therapy, OriCAR-017, has been granted approval for clinical trials. The therapy is intended for the treatment of recurrent refractory multiple myeloma (R/R MM). GPRC5D as a Therapeutic Target…
